

Mortality Associated with the Use of Inappropriate Drugs According Beers Criteria: a Systematic Review

Karina Sichieri¹, Adriano R. Baldacin Rodrigues², Juliana A. Takahashi³, Silvia Regina Secoli⁴, Moacyr Roberto Cuce Nobre⁵, Martinez Altava Mónica⁶, Fernández Garrido Julio^{7,*}

¹University Hospital, University of São Paulo

²Nurse, Heart Institute, Hospital Clinic of the Faculty of Medicine, University of São Paulo

³Librarian of the School of Nursing, University of São Paulo

⁴Associate Professor of Medical-Surgical Department, School of Nursing, University of São Paulo

⁵Teacher and researcher associated with the Clinical Epidemiology Unit of the Heart Institute, Hosp. Cl. Of the Faculty of Medicine, University of São Paulo

⁶Research Nurse. General University Hospital in Castellon (Spain).

⁷Professor of Faculty of Nursing and Podiatrics. University of Valencia (Spain)

*Corresponding Author: julio.fernandez@uv.es

Copyright © 2013 Horizon Research Publishing All rights reserved.

Abstract The aims of this systematic review are to identify and analyse the scientific literature available evidence about the use of potentially inappropriate medications, according to the Beers Criteria, that is associated with mortality in the elderly people. It has been made a search of publications in most traditional electronic databases among the scientific community (Pubmed / Medline, EMBASE and Web of Science) and it has been selected publications that obey the criteria of 'observational study', 'elderly' and 'Beers Criteria' and that they had as a result the mortality of the study population. After publications selection it proceeded to dump data by two researchers independently to avoid selection bias. The methodological quality of the selected studies was assessed by the checklist Newcastle-Ottawa. The final sample of this systematic review has been made up of 17 studies published in Pubmed and Embase databases majority, 8 of which make up the meta-analysis. In descriptive synthesis has been observed that most of the studies have a level of evidence IV (94.1%) with cohort delineation (94.1%) and non-probability sampling technique (70.6%). Data collection was prospective in 58.8% of cases, with a sample (n) greater than 1000 elderly (64.7%) and followed up for 6 to 12 months (52.9%). The meta-analysis involving 90.611 elders informed that users who take inappropriate drug according to the Beers Criteria had a higher relative risk for mortality outcome (RR = 1.11, 95% CI 1.01-1.22 P = 0.023), regardless of study stage, comorbidity presence, polypharmacy or type of inappropriate medication used.

Keywords Elderly, Inappropriate Medication, Mortality, Systematic Review, Meta-Analysis, Beers Criteria

1. Introduction

The current demographic changes, generally characterized by a dramatic improvement in life expectancy and resulting increase in population rates aging is, among other things, showing new health needs, among which include high frequency of comorbidities and using associated polypharmacy. The multiple disorders and their treatments can become triggers for adverse effects associated with potentially inappropriate prescribing drugs that often involves clinical complications and adverse effects on health and disease control.

The use of polypharmacy in elderly, along with aging metabolic changes, has been generating some controversy and doubts about the suitability use of some drugs while on the impact of these drugs, potentially inappropriate, may have on mortality among elderly population. However, despite clinical suspicion, there seems no sufficient scientific evidence to claim that potentially inappropriate medication use (IMU) in the elderly is associated with mortality, so that posed a literature analysis to try to find these evidence. As a reference tool of inappropriate medications it has worked with the Beers criteria, which includes 41 drugs or classes of drugs considered inadequate to use with elderly in any situation and 7 considered unsuitable according to circumstances or doses, both groups also classified according to severity, high or low.

2. Materials and Methods

It conducted a systematic review of published studies in electronic databases that showed a positive relationship between inappropriate drug prescription in the elderly and mortality outcome, in order to identify and analyse evidence on the association of use potentially inappropriate drug in the elderly according Beers (IMU) and mortality.

It has been used the Beers criteria because is the most

widely used internationally to assess the drug therapy adequacy in the elderly.

It was included in the analysis all observational studies conducted with people over 65 years old (in developed countries) or 60 (in developing countries), regardless of the study context (hospital, outpatient or home) and that would make reference to the drugs misuse as the Beers criteria (1991, 1997 and 2003) resulting in death.

It was established as the analysis period, studies published between 1991 (first publication year of Beers criteria) and 2010.

It were excluded from RS, the study sample of frail elderly, because it not determine whether this circumstance was significantly determined outcome of mortality, and also those that show intermediate results, such as RAMs, falls, hospitalizations or other, that somehow could have a decisive influence as a mortality cause.

The databases searched were: Bank CAPES thesis, CINAHL, *Current contents connect*, Embase, *International Lilacs*, *Pharmaceutical Abstracts*, *Proquest dissertation and Theses*, Pubmed / Medline, Scopus, *Web of Science* and *Science direct*.

The initial search provided a total of 1193 articles, their methodological rigor was analysed by Newcastle-Ottawa checklist. After removing duplicate articles or those considered with insufficient scientific rigor, it leaved a sample of 1042 items (n = 1042) they were analysed by title and abstract by two researchers independently. Each overturned different data items to a database consisting of following variables: number of study; publishing-related variables (database, type of publication, country, language, authors and area of operation), study purpose, method-related variables (study design, duration, data collection, sample type, stage version of the Beers criteria, outcome information source and age), characteristics of the sample (mean age, sex, level of comorbidities, chronic diseases number, diagnosis, activities assessment of daily living, cognitive assessment, number of drug or class of drugs used), IMU (incidence, number of people who took at least one IMU and its characteristics-gender, age, comorbidities, number of medications-) and results (number

of people who died and made use of IMU, measure of *effect*, confidence intervals, p value and author's conclusion) and evidence level too.

In 12 of the cases were sent an email to the study authors to complete the information specified. It expanded information in 3 cases, but the remaining 9, 3 authors had no more data and 6 did not respond.

In meta-analysis conducting it adopted a random effects model inclusive for subgroup analysis because all studies had different characteristics: different ages of elderly and health conditions, evaluation of IMU by the Beers criteria in 3 different versions and healthcare scenarios differentiated. These different characteristics collected in the analysed studies led to diversity and heterogeneity existence, so the random effect values the contribution of small studies giving results in a wider confidence interval.

In this RS it's considered the heterogeneity test.

Synthesis measurement were taken effect relative risk and the required number of users-cases in which IMU used gave a mortality result (NNH) used to measure complement intervention impact of IMU use.

To check the strength of the results of the meta-analysis was performed a subgroup analysis considering outcome studied (mortality), IMU evaluation by the Beers criteria 2003 version; as a backdrop, the hospital (n = 8).

The meta-analysis was performed with L.Bax MIX 2.0 *Professional software for meta-analysis in Excel version* (2.01.0) Biostat XL 2010 program.

By having an outcome so defined (mortality), it is use controlled descriptors and keywords as specified search strategy seeking to obtain more relevant studies. However, in the preliminary phase, found no systematic review databases RS (Bandolier, Clinical Evidence, Cochrane Library and other). This study systematic review databases were located in Pubmed / Medline and EMBASE, mostly.

Table No. 1 shows controlled and uncontrolled descriptors for each study used in search, according to PICO* strategy.

Time limit was established as early 1991, because it was the year that Beers criteria arises. As a final limit it was established in 2010.

Table 1. Controlled and uncontrolled descriptors used in the search, according to PICO strategy in this SR

P	MESH descriptor (Pubmed/Medline)	Aged/ “aged, 80 and over”
	Uncontrolled descriptor	centenarian (s) / nonagenarian (s) / octogenarian (s) / senior (s) / geriatric / elder (s) / older / old / ancient
I	MESH descriptor	“inappropriate prescribing”
	Uncontrolled descriptor	“inappropriate prescription (s)” / suboptimal prescribing” / “inappropriate medication (s)” / “inappropriate drug (s)” / “inappropriate medicine (s)” / “inadequate prescribing” / “inadequate prescription (s)” / “suboptimal prescription (s)” / “suboptimal therapy” / “inadequate medications” / “drug related problem (s)” / “medication-related problem (s)” / beers / “beers criteria” / “beers list”
O	MESH descriptor	Mortality / “mortality [subheading]” / “hospital mortality” / death / “outcome assessment (health care)”
	Uncontrolled descriptor	“adverse drug event (s) / “adverse event (s)” / outcome (s) / mortalities / deaths / “adverse medication events”
P	DECS descriptor (LILACS)*	<i>Idoso</i>
	Uncontrolled descriptor	/
I	DECS descriptor	<i>“Prescrição inadequada” / “uso de medicamento” / “preparações farmacêuticas”</i>
	Uncontrolled descriptor	<i>“medicamento potencialmente inapropriado”</i>
P	EMTREE descriptor (EMBASE)	Aged / “aged hospital patient” / “very elderly” / “geriatric patient”
	Uncontrolled descriptor	centenarian (s) / nonagenarian (s) / octogenarian (s) / elder (s) / older / old
I	EMTREE descriptor	“inappropriate prescribing” / prescription / drug / “drug therapy”
	Uncontrolled descriptor	“suboptimal prescribing” / “inappropriate medication (s)” / “inappropriate drug (s)” / “inappropriate medicine (s)” / “suboptimal prescription (s)” / “suboptimal medication” / “suboptimal drug” / “inadequate medication (s)” / “inadequate prescribing” / “inadequate prescription (s)” / “inadequate drug (s)”
O	EMTREE descriptor	mortality / death / “adverse outcome” / “drug fatality”
	Uncontrolled descriptor	“adverse drug event (s)”
P	CINAHL descriptor	aged / “aged, 80 and over” / “aged hospitalized”
	Uncontrolled descriptor	centenarian (s) / nonagenarian (s) / octogenarian (s) / senior (s) / geriatric / elder (s) / older / old / ancient / elderly
I	CINAHL descriptor	drugs / “prescribing patterns” / “drug therapy” / “prescription, drug” / drug utilization”
	Uncontrolled descriptor	medication (s) / medicine (s) / prescribing / prescription (s) / inappropriate / inadequate / suboptimal
O	CINAHL descriptor	mortality / “hospital mortality” / death / “outcome assessment” / “outcome (health care)”
	Uncontrolled descriptor	outcome (s) / “adverse event (s)” / mortalities / deaths / “adverse drug event (s)” / “adverse medication event (s)”

*Lilacs: portuguesedatabase ;P:patient/population I:intervention/indicator C: comparison/control O: outcome

3. Results

The results are grouped by the following items: study selection process, publications characterization (general, methodological approach) sample characteristics, IMU description, elders groups who used or not IMU and the respective measures effect on the outcome, meta-analyses and subgroup analyses IMU classified by the Beers criteria (2003) and mortality in the hospital setting.

Of the eleven electronic databases consulted in the first stage of study, most studies identifying occurred in Science Direct (n = 244, 20.5%) and Web of Science (n = 215, 18.0%).

Of the studies reviewed holistically, the 27.5% were found in the Pubmed / Medline database (n = 25), the 24.2% in Embase (n = 23) and 23.4% in IPA (n = 15).

Of the initially selected studies (n = 1193) were excluded 151 (12.7%) because they were duplicates and 1042 (87.3%) remaining 1002 were further excluded after reading the abstract, thus leaving 40 (3.8%) studies who underwent a comprehensive reading.

Comprehensive reading revealed that 25 jobs (2.4%) were on non-relevant aspects to the review, which 15 (1.4%) were finally suitable for the sample, but when reviewing the references of these 15 studies, was decided to analyse and include two more articles in the final sample being selected a total of n = 17.

The following Table 2 shows the articles general characteristics included in this SR:

Regarding the methodological approach, we found that most of the studies had a level of evidence IV (n = 16; 94.1%) with cohort delineation (n = 16; 94.1%), non-probability sampling technique (n = 12; 70.6%), data collected prospectively (n = 10, 58.8%), larger sample of 1000 elderly (n = 11; 64.7%) with following of 12-24 months (n = 9, 52.9%) and mortality results obtained by database query (n = 13; 76.5%).

Regarding the characteristics of the sample, showed that the majority of studies involved mainly female individuals (n = 16; 94.1%) with an average age greater than 70 years (n = 14, 82.4%) and using at least two drugs (n = 15; 88.2%).

In 9 of the 17 studies (52.9%), the researchers described the number of comorbidities using the Charlson comorbidity index (n = 5; 29.4%).

Others 9 (52.9%) also described the elderly functional assessment by scales Barthel, Katz and others.

The mean number of drugs used in the elderly was higher in those studies examining medicines use in long-standing institutions (E1¹, E3⁶, E9⁴, E14²¹, and in Table 2) than in the hospital setting (E4²⁴, E6¹⁸, E12¹⁹, E16⁵, in Table 2) and this, more than in the community (E1¹, E2², E5²³, E10⁸, E13¹³, E15¹¹, in Table 2).

C: community; LSI: long-standing institution, ND: data not described in the study

In most studies (n = 12; 70.5%) IMU was classified as an inappropriate drug independently of diagnosis, therapy dose or time. In 23.5% of cases (E3⁶, E6¹⁸, E11¹⁴, E16⁵) it's given a more extended classification, taking into account the drug-pathology interaction condition. Of these four studies, only 2 reported the results.

Table 2. General characteristics of the publications included in the SR

Studio	Authors	Title	Journal/year	Publication language (country of publication)	Knowledge area	Database
E01 ¹	Barnett K, McCowan C, Evans JMM, Gillespie ND, Davey PG, Fahey T	Prevalence and outcomes of use of potentially inappropriate medicines in older people: Cohort study stratified by residence in nursing home or in the community	BMJ Quality and Safety/ 2011	English (UK)	Public Health	Embase; Web of science; Pubmed; CINAHL
E02 ²	Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, Flicker L	Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study	British Journal of Clinical Pharmacology/2011	English (AUST)	Medicine	Pubmed
E03 ⁶	Dedhiya SD, Hancock E, Craig BA, Doebbeling CC, Thomas J	Incident Use and Outcomes Associated With Potentially Inappropriate Medication Use in Older Adults	The American Journal of Geriatric Pharmacotherapy/2010	English (USA)	Pharmacy	Pubmed; Embase; Scopus; Web of Science
E04 ²⁵	Szlejfc	Eventos adversos médicos em idosos hospitalizados: frequência e fatores de risco em enfermagem de geriatria	PhD thesis/2010	Portuguese (BRA)	Medicine	CAPES

E05²³	Pozzi C, Lapi F, Mazzaglia, G, Inzitari M, Boncinelli M, Geppetti P, Mugelli A, Marchionni N, Bari M	Is suboptimal prescribing a risk factor for poor health outcomes in community dwelling elders? The ICARE-Dicomano study	Pharmacoe pidemiology and Drug Safety/2010	English (ITALY)	Medicine	Pubmed; Embase; Web of Science
E06¹⁸	Mansur N, Weiss A, Belosey Y	Is there an association between inappropriate prescription drug use and adherence in discharged elderly patients?	The annals of Pharmacotherapy/2009	English (ISRAEL)	Medicine	Pubmed; Embase; IPA; Scopus; Web of Science
E07¹⁵	Lin H, Liao C-C, Cheng S-H, Wang P-W, Hsueh Y-S	Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases - Experience in a Taiwanese Medical Setting	Drugs Aging/2008	English (TAIWAN)	Pharmacy	Pubmed; Scopus; Embase; IPA; Web of science; CINAHL; Current Contents Connect
E08²¹	Page RL, Ruscini JM	The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use	The American Journal of Geriatric Pharmacotherapy/2006	English (USA)	Pharmacy	Science direct; Scopus; Pubmed
E09²⁴	Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH	Use of Inappropriate Medications and Their Prognostic Significance Among In-Hospital and Nursing Home Patients with and without Dementia in Finland	Drugs Aging/2006	English (FINLAND)	Medicine	Embase; Current Contents Connect; Web of Science; IPA; CINAHL
E10⁸	Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, Markides K.	Suboptimal medication use and mortality in an older community based cohort: results from the Hispanic EPESE Study	Journals of gerontol. Series A, Biological sciences and medical sciences/2006	English (USA)	Medicine	References
E11¹⁴	Lau DT, Kasper JD, Potter DEB, Lyles A, Bennett RG	Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents	Arquives of Internal Medicine/2005	English (USA)	Medicine	Pubmed; Web of Science; IPA; Embase; Current Contents Connect; Scopus
E12¹⁹	Onder G, Landi F, Liperoti R, Fialova D, Gambassi G, Bernabei R	Impact of inappropriate drug use among hospitalized older adults	European Journal of Clinical Pharmacology/2005	English (ITALY)	Medicine	Pubmed; Web of Science; Current Contents Connect; Scopus
E13¹³	Klarin I, Wimo A, Fastbom J	The association of inappropriate drug use with hospitalisation and mortality - A population-based study of the very old	Drugs Aging/2005	English (USA)	Public Health	Pubmed; Scopus; Embase; IPA; Web of science; CINAHL; Current Contents Connect

E14²¹	Perri III M, Menon AM, Deshpande AD, Shinde SB, Jiang R, Cooper JW, Cook CL, Griffin SC, Lorys RA	Adverse outcomes associated with inappropriate drug use in nursing homes	The Annals of Pharmacotherapy/2005	English (USA)	Pharmacy	PubMed; Embase; Web of Science; IPA; Scopus
E15¹¹	Hanlon JT, Fillenbaum GG, K uchibhatla M, Artz MB, Boulton C, Gross CR, Garrard J., Schumaker KE	Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders	Medical care/2002	English (USA)	Pharmacy	Scopus; Web of Science; CINAHL; PubMed
E16⁵	Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PD	Appropriateness of medication selection for older persons in an urban academic emergency department	Academic Emergency Medicine/1 999	English (USA)	Medicine	PubMed; Embase; Web of Science; Scopus
E17¹⁰	Gupta S, Rappaport HM, Bennett LT	Inappropriate Drug Prescribing and Related Outcomes for Elderly Medicaid Beneficiaries Residing in Nursing Homes	Clinical Therapeutics/1996	English (USA)	Pharmacy	References

Table 3. Features based on the sample of seniors in the studies included in the SR.

Studio	Sex	Age (mean in years)	Diagnosis	number of chronic diseases(mean)/ scale of comorbidities (mean)	functional evaluation	cognitive evaluation	number of drugs / class of drugs used mean
E1¹	C: 57'0% female LSI: 72'3% female	66 to 99 (C: 75'2 LSI: 84'5)	ND	ND	ND	ND	C: mean - 8,8 classes / elderly LSI: 11'6 mean class / elderly
E2²	100% male	65 to 83 (77)	ND	Charlson 1-2 points (19'2%)	ND	ND	≥5 drugs: 35'8% elderly
E3⁶	76'5% female	≥ 65 (83'1)	ND	Charlson: 2'25	ND	ND	1 to 10: 24'3% elderly 11 to 15: 28'3% elderly 16 to 20: 23'4% elderly +20: 24'0% elderly Mean: 5'73 drugs
E4²⁵	59'1% female	≥ 60 (78'1)	Depression (18'7%) Dementia (29'8%) Delirium (35'7%) Infection (55'6%)	Charlson: 3'07	Katz index independent Mean: 4'13	ND	Mean: 5'73 drugs
E5²³	57'1% female	≥ 65 (73±6'8)	ND	2'3 diseases	Disability in basic activity = 7'5% Disability in instrumental activity = 32%	ND	Mean: 2'2 drugs/elderly ≥5 drugs: 12'3%
E6¹⁸	61'8%	≥ 65	Neurological (18%)	6'3	Katz index	Mini-me	5'9 at discharge

	female	(81'1)	Orthopaedic (18%) Fall and imbalance (15%) Hemato-oncology (11%)	diseases	Independent (58%) Partial (27'4%) Total (14'6%)	ntal: Normal (78'8%) Mild to moderate (12'7%) Severe (8'5%)	6'5 after a month of discharge
E7¹⁵	55'5% female	≥ 65 (74'7)	Hypertension (24'2%) Heart disease (14'1%) Diabetes mellitus (11'5%)	1 disease (27'8%) 2 diseases (46%) 3 diseases (21'2%) ≥ 4 diseases (5%)	ND	ND	≤4 drugs (80'8%)
E8²¹	68'9% female	≥75 (79)	ND	ND	ND	ND	ND
E9²⁴	82'0% female	≥ 70 (86)	ND	Charlson Scale Dementia > 2 points (42'4%) Without dementia: > 2 points (30'6%)	Clinical Dementia Rating scale Dependence among elderly with dementia: 76'9% Dependence among older adults without dementia: 21'2%	Mini-mental Dementia 9'9 points (mean)	Mean: 9'0 drugs
E10⁸	64'5% female	65 to 99 (73)	Cardiovascular disease (12'5%) Neoplasia (6'3%) Diabetes mellitus (32'9%) Hypertension (56'9%)	ND	<i>Older American Resource Scale</i> Disability in basic activity = 14'5% Disability in instrumental activity = 41'5%	ND	>4 Drugs=21'1%
E11¹⁴	73'8% female	≥ 65	Dementia (47'7%)	ND	0-3 limitations (26'3%) 4-5 limitations (30'3%) 6 limitations (46'2%)	ND	ND
E12¹⁹	52'2% female	≥ 65 (78'8)	Hypertension (37'8%) Ischemic heart disease (27'6%) Heart failure (21'5%) Diabetes (20'2%)	Charlson ≥2 points (47'8%)	Disability in basic activity = 38'5%	Cognitive impairment (34'6%)	≥5 drugs: 74'3%
E13¹³	57'9% female	≥ 75 (82'6)	ND	ND	ND	ND	Mean: 4'4 drugs ≥5 drugs: 40'1%
E14²¹	81'6% female	≥ 65 (84'6)	Dementia (70'5%) Heart disease (66'9%) Hypertension (57'1%)	ND	ND	ND	Mean: 8'7 drugs ≥5 drugs: 76'5%
E15¹¹	64'8% female	≥ 65	ND	ND	Katz Index, Older American Resource Scale and Rosow-Breslau Scale Disability in one or more basic activity: 18'3% Disability in instrumental activity = 35'5%	Cognitive impairment (15'8%)	2 to 4 drugs: 42'9%
E16⁵	63'0% female	≥ 65 (76'3)	ND	1'8 diseases	Inability to, at least, one basic activity: 57%	ND	Mean: 3'6 Drugs: 73'6%
E17¹⁰	73'6%	60'1% -	ND	ND	ND	ND	ND

female ≥81

C: community ND: Not described LSI: long standing institution

In the overall analysis following IMU were important:

Table 4. Drug groups most commonly found

DRUG GROUP	Gravity according side effects probability	n
Anticholinergic-Antihistamines	High	9
Benzodiazepines	High	10
Tricyclicantidepressants	High	10
Antiplatelet	Low	8
Musclerelaxants	High	6
Antispasmodics	High	8
Digoxin	Low	6
Ferroussulphate	Low	6

Whichever version of Beers and studied scenario is agreement between the different studies that benzodiazepine (BDZ) are the drugs most identified as IMU. The long-acting BDZ should be avoided entirely in this population because of its effect of prolonged sedation, risk of falls and consequent fractures. Secondly, tricyclic antidepressants, antihistamines and anticholinergic also achieve high frequency as IMU and should be avoided due to their sedative and central nervous system depressants.

Reviewing Beers 2012 includes this recommendation cited and classified as evidence IV and recommendation grade D.

The 47.1% studies used Beers version 2003 (E1¹, E2², E3⁶, E4²⁵, E6¹⁸, E7¹⁵, E8²¹, E12¹⁹, and in Table 2).

The measure of studies effect was the *Odds ratio* (n = 7; 41.2%).

In most of the studies (n = 11; 64.7%) authors observed no association between the use of IMU and mortality. Only in 3 of them (E3⁶, E11¹⁴, E14²¹, in Table 2) it was showed this association.

Were included in the meta-analysis 8 items (E1¹, E3⁶, E4²⁵, E5²³, E7¹⁵, E8²¹, E9²⁴, E12¹⁹ in Table 2) with a total of 90611 participants aged. Here there was a statistically significant difference between elderly groups (p=0.022) regardless to mortality and a large heterogeneity of the studies (I²= 53.8 6%).

Regarding the subgroup analysis, it was performed with 6 studies using Beers version 2003, with a total of 89164 users verifying an statistical difference among elderly users of IMU for mortality risk (p=0.021) and with great heterogeneity (I²=62.09%).

Subgroup analysis on the 3 studies conducted in hospitals (E4²⁵, E6¹⁸, E12¹⁹, n=5530 elderly) demonstrated no statistical difference groups with mortality as a result (p=0.246) and moderate heterogeneity (I² = 28.91%).

Table 5 shows the synthesis of meta-analysis results including subgroup analysis.

Table 5. Summary of results of meta-analyses, including subgroup analyses.

Outcome	Number of studies	Total patients	Q (p)	I ² (IC 95%)	overall estimate (IC 95%)	p	NNH	Conclusion
Mortality from all causes	8	90611	15.17 (0.033)	53.86% (0 a 79)	1.11 (1.01 a 1.22)	0.022	36	Statistical difference
Mortality versus Beers 2003 standard	6	89164	13.18	62.09% (7 a 84)	1.12 (1.02 a 1.25)	0.021	33	Statistical difference
Mortality in the hospital	3	5.530	2.81 (0.244)	28.91% (0 a 92)	0.81 (0.57 a 1.15)	0.246	151	No statistical difference

4. Discussion

This SR has found evidence to suggest that the elderly who used IMU had higher relative risk of death (RR=1.11, 95% CI 1.01-1.22, $p=0.023$), according Beers criteria, regardless of the stage of study, comorbidities, polypharmacy or type of IMU used.

In descriptive synthesis were included 1.6% of the total studies reviewed by title and abstract, results were quite similar to other RS that analysed the use of IMU (2%, 3%)^{7, 9, 20}.

This SR also found as general common characteristics to other studies the close relationship between aging and criteria development to assess the quality of care. Generally, these studies were conducted in developed countries, being USA the first to develop a criterion for classifying IMU.

The study has been carried out predominantly from cohort studies, predominantly those of nature population and hospital environment held in long-stay institutions, with prospective data collection and non-probability sampling. Although it no represents the highest level of evidence, Phase IV studies whose data are obtained from databases are particularly relevant because the information has been obtained from actual conditions (heterogeneous population from various care settings and representative actual health services).

The profile of the sample of elderly, found that female sex is prevalent in all studies of the SR, except one (E2², in Table 2). This can be explained because older women tend to live longer than men, regardless of the stage and health conditions, older women are more likely to use IMU.

This association of women and IMU may be due to biological matters (most exposed to health problems), psychological (worry more about their health / symptoms) and socio-cultural (most frequently used health services).

In previous SR also showed that female gender is a risk factor associated with the use of IMU^{3, 4, 16, 17}

In all studies, age adopted the "elders" was in > 65 years, according to the WHO, except Brazil, which defined over 60 years old as a person aged.

In reference to the characteristics of the sample were found to age, number of diseases and medicines as well as the setting of care are variables that must be considered together because of their close relationship, because the older, larger number of diseases and drugs to treat. In addition there is usually an increase in hospitalizations number, and this population, are the ultimate users of long-stay facilities (nursing homes).

The analysis reveals that the average age > 80 years and the average number of drugs consumed were higher for institutionalized elderly. These are generally more vulnerable to IMU use as other groups of elderly due to frailty and comorbidity present. Also showed that is a risk associated with the use of IMU in long-stay institutions have more than 85 years and comorbidity (> 3 Charlson index).

Moreover, the existence of multiple physicians

prescribing carries an increased risk of polypharmacy, which in turn is set as a contributing factor to use of IMU. This is especially common in long-stay institutions which is corroborated by the evidence that SR has shown that the use of IMU is more pronounced among institutionalized elderly that in other healthcare settings.

The fact that in some studies the authors did not clearly define the IMU concept (in terms of dose or therapy time) can be confusing, but always has been associated with older people.

In the meta-analysis were included 8 studies reporting results with absolute frequency on sample and the results analysed, mortality. For this result was statistically significant difference ($p = 0.02$, 95% CI 1.01-1.22) between the two groups showing the harmful effects of the use of IMU for elderly as mortality outcome. This relationship, against the non-confirmation on the previous SR and refuted in other studies of the SR, is also found in three studies (E3⁶, E11¹⁴, E14²¹, in Table 2) who obtained higher risk of death for the elderly in the IMU use.

The studies heterogeneity was large ($I^2=53.86\%$) due to the differences in study scenarios (long-stay institutions (LSI), hospital and community, and community LSI), comorbidities users profile, number and class of drugs used as well as differences between drugs among countries.

In the subgroup analysis ($n=5530$) in hospital setting, there was less heterogeneity of the studies ($I^2=28.91\%$) because users came from hospitals and drugs were classified according to 2003 Beers.

The meta-analysis, provides no statistically significant difference between the groups, but showing a trend of lower mortality risk for elderly IMU users. This could be explained because in the hospital environment more patients are supervised by professionals on adverse drug effects and prescribing precautions IMU. However, more studies are needed to reinforce or refute these hypotheses given the weakness of the data.

The use of random effect in this SR is justified by the studies diversity and heterogeneity. This model values small studies contribution providing a broader IC.

NNH calculation for mortality from all causes was 36, i.e., for every 36 seniors who used IMU, one would die. In subgroup analysis yielded a similar result, NHH=33. By contrast, in subgroup analysis carried out with hospital studies was NHH = 151, which, in accordance with meta-analysis interpretation, we infer that the use of IMU in hospital setting protects the elderly of mortality outcome since each 151 IMU user, one perish.

Drug therapy responds to the balance between the benefit and the harm a drug can bring. That is, the drug is prescribed looking for a positive effect of the same in order to try to improve individuals' health because generally, without the drug, there's not an improvement in health, sometimes even more damage. The problem arises in these patients with multiple disorders and visits to different specialists, each one prescribing in their health branch, may guide to incompatible

pharmacology situations and side effects, usually negative (morbidity and mortality). Thus the use of drugs requires an integrated interdisciplinary management and with the help of tool in health posed by the Beers criteria, Professionals can carry it out. The fact that an IMU-mortality relationship has been established, although not clearly evidenced yet, should encourage practitioners to treat pharmacologically with care on users and find strong results about it.

5. Limitations

This RS found limited to information availability from primary studies. The absence of responses to requests made to the authors of primary studies did not enable the inclusion of several studies in the meta-analysis, having been able to increase the sample to strengthen, with the possibility of showing a different result.

Moreover, comorbidity, different drugs, and the type of facility or research context are a limitation by itself because heterogeneity that each of these variables can result.

REFERENCES

- [1] Barnett K, McCowan C, Evans JMM, Gillespie ND, Davey PG, Fahey T. Prevalence and outcomes of Potentially Inappropriate use of medicines in older people: Cohort study stratified by residence in nursing home or in the community. *BMJ Qual Saf*. 2011, 20 (3) :275-81.
- [2] Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, et al. Quality use of medicines and health outcomes Among a cohort of community dwelling older men: an observational study. *Br J Clin Pharmacol*. 2011, 71 (4) :592-99.
- [3] Bierman AS, Pugh MJV, Dhalla I, Amuan M, Fincke G, Rosen A, et al. Sex differences in prescribing Inappropriate Among elderly veterans. *Am J Geriatr Pharmacother*. 2007;5:147-161.
- [4] Buck MD, Atreia A, Brunner CP, Jain A, Suh TT, Palmer RM, et al. Potentially Inappropriate medication prescribing in outpatient practices: Prevalence and Characteristics based on electronic patient health records. *Am J Geriatr Pharmacother*. 2009;7 (2) :84-92.
- [5] Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, et al. Appropriateness of medication selection for older persons in an urban academic emergency department. *Acad Emerg Med* 1999;6 (12) :1232-42.
- [6] Dedhiya SD, Hancock E, Craig BA, Doebbeling CC, Thomas J. Incident use and outcomes Associated with Potentially Inappropriate medication use in older adults. *Am J Geriatr Pharmacother*. 2010, 8 (6) :562-70.
- [7] Dimitrow MS, Airaksinen MSA, Kivela SL, Lyles A, Leikola SNS. Comparison of prescribing criteria to evaluate appropriateness of drug treatment in Individuals aged 65 and older: a systematic review. *JAGS*. 2011;59:1521-30.
- [8] Espino DV, OV Bazaldua, Palmer RF, Mouton CP, Parchman ML, Miles TP, Markides K. Suboptimal medication use and mortality in an older community based cohort: results from the Hispanic EPESE Study. *J Gerontol A Biol Sci Med Sci* 2006;61 (2) :170-5.
- [9] Guaraldo L, Cano FG, GS Damasceno, Rozenfeld S. Inappropriate medication use Among the elderly: a systematic review of administrative databases. *BMC Geriatrics*. 2011;11:79.
- [10] Gupta S, Rappaport HM, Bennett LT. Inappropriate Drug Prescribing and Related Outcomes for Elderly Medicaid Beneficiaries Residing in Nursing Homes. *Clin Ther*. 1996, 18 (1) :183-96.
- [11] Hanlon JT, Fillenbaum GG, Kuchibhatla M, Artz MB, Boulton C, Gross CR, et al. Impact of Inappropriate drug use on mortality and functional status in representative community dwelling elders. *Care Med*. 2002, 40 (2) :166-76.
- [12] Janus E, Aparasu R. Healthcare Associated outcomes with beers' Criteria: a systematic review. *Geriatrics*. 2007;41:438-48.
- [13] Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalization and mortality. A population-based study of the very old. *Drugs Aging*. 2005, 22(1): 69-82.
- [14] Lau DT, Kasper JD, Potter DEB, Lyles A, Bennet RG. Hospitalization and Death Associated with Potentially Inappropriate medication prescriptions Among elderly nursing home residents. *Arch Intern Med* 2005, 165:68-74.
- [15] Lin H, Liao CC, Cheng SH, Wang PW, Hsueh YS. Association of Potentially Inappropriate Use With medication adverse outcomes in ambulatory elderly patients with chronic diseases -experience in a Taiwanese medical setting. *Drugs Aging*. 2008, 25 (1) :49-59.
- [16] Locatelli J, Lira AR, Torraga LKLA, AT Paes. Inappropriate medication using the Beers criteria in Brazilian elderly hospitalized patients. *Consult Pharm*. 2010;25:36-40.
- [17] Maio V, Del Canale S, Abouzaid S. GAP Investigators. Using explicit criteria to evaluate the quality of prescribing in elderly Italian outpatients: a cohort study. *J Clin Pharm Ther*. 2010;35:219 - 229.
- [18] Mansur N, Weiss A, Beloosesky Y. Is there an association Between Inappropriate prescription drug use and adherence in discharged elderly patients? *Ann Pharmacother*. 2009, 43 (2) :177-84.
- [19] Onder G, Landi F, Liperoti R, Fialova D, Gambassi G, Bernabei R. Impact of Inappropriate drug Use among hospitalized older adults. *Eur J Clin Pharmacol*. 2005, 61:453-9.
- [20] Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. *PLoS ONE*. 2012, 7 (8): e43617.
- [21] Page RL, JM Ruscin. The risk of adverse drug events and hospital related morbidity and mortality Among older adults with Potentially Inappropriate medication use. *Am J Geriatr Pharmacother* 2006;4 (4) :297-305.
- [22] Perri III M, Menon AM, Deshpande AD, Shinde SB, Jiang R,

- Cooper JW, et al. Associated with Adverse outcomes Inappropriate drug use in nursing homes. *Ann Pharmacother.* 2005, 39 (3) :405-11.
- [23] Pozzi C, Lapi F, Mazzaglia G, Inzitari M, Boncinelli M, Geppetti P, et al. Suboptimal prescribing Is a risk factor for poor health outcomes in community-dwelling elders? *TheiCareDicomano study. PharmacoepidemiolDrugSaf.* 2010, 19 (9) :954-60.
- [24] Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, PITK ä 1 äKH. Inappropriate Use of Medications and Their Prognostic Significance Among In-Hospital and Nursing Home Patients with and without Dementia in Finland. *Drugs Aging.* 2006, 23 (4) :333-43.
- [25] Szejf C. Eventos adversos medicosemidosos hospitalizados: frequência e fatores de risco em enfermagem de geriatria [tese]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 2010